Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 17, Issue 2, pp. 554-564
PubMed
Published By
Print ISSN
Online ISSN
History
- Received August 4, 2017
- Revision received September 19, 2017
- Accepted November 9, 2017
- Published first November 15, 2017.
Article Versions
- Previous version (November 15, 2017 - 09:02).
- Previous version (January 19, 2018 - 08:02).
- You are viewing the most recent version of this article.
Copyright & Usage
©2017 American Association for Cancer Research.
Author Information
- Fu Li1,*,
- May Kung Sutherland1,
- Changpu Yu1,
- Roland B. Walter2,3,
- Lori Westendorf1,
- John Valliere-Douglass4,
- Lucy Pan4,
- Ashley Cronkite1,
- Django Sussman1,
- Kerry Klussman1,
- Michelle Ulrich1,
- Martha E. Anderson1,
- Ivan J. Stone1,
- Weiping Zeng1,
- Mechthild Jonas1,
- Timothy S. Lewis1,
- Maitrayee Goswami5,
- Sa A. Wang5,
- Peter D. Senter1,
- Che-Leung Law1,
- Eric J. Feldman1, and
- Dennis R. Benjamin1
- 1Translational Research, Seattle Genetics, Inc. Bothell, Washington.
- 2Fred Hutchinson Cancer Research Center, Seattle, Washington.
- 3Division of Hematology and Department of Medicine, University of Washington, Seattle, Washington.
- 4Analytical Science, Seattle Genetics, Inc., Bothell, Washington.
- 5Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- ↵*Corresponding Author:
Fu Li, Seattle Genetics, Inc., 21823 30th Drive South East, Bothell, WA 98021. Phone: 425-527-4626; Fax: 425-527-4609; E-mail: fli{at}seagen.com
February 2018
Volume 17, Issue 2
Volume 17, Issue 2
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Jump to section
Advertisement